Preclinical development and selection of nanobody-based CAR-T cells targeting HER2-positive solid tumors
Molecular Therapy Oncology · 2025-12 · 33 (4) · 201088
DOI: 10.1016/j.omton.2025.201088 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy Oncology, 2025-12. Verfasst von Fien Meeus und 10 weiteren Autor:innen. Beteiligte Einrichtung: Vrije Universiteit Brussel (VUB), Translational Oncology Research Center, Department of Biomedical Sciences, Molecular and Cellular Therapy Research …. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fonds Wetenschappelijk Onderzoek, Vrije Universiteit Brussel, Kom op tegen kanker.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR)-T cell therapy revolutionized treatment of hematological malignancies, but translation to solid tumors remains difficult. Therefore, different avenues are explored to develop novel CAR-T cell products. Nanobodies have advantageous features for CAR design, such as ease of engineering and low immunogenicity, but predictive values on nanobody characteristics for optimal CAR-T cell function remain unclear. We performed a side-by-side evaluation of 12 nanobody-based (nano)CARs against human epidermal growth factor receptor 2 (HER2). All nanoCARs showed the ability to activate a reporter T cell line upon recognition of HER2pos cells. When evaluated in primary T cells, 6/12 nanoCARs showed the strongest reactivity and cytotoxicity against HER2pos glioblastoma and breast cancer cells. Moreover, only 1/12 was able to confer potent cytotoxicity against HER2pos melanoma cells. These data add to the current view that nanobody selection for CAR design remains subject to extensive side-by-side screening. Still, superior cytotoxicity across multiple solid tumor cell lines-determined using in vitro assays evaluating activation, cytokine secretion, and target cell-specific killing-led to selection and further characterization of a lead nanoCAR 1R59b, showing tumor control in an in vivo xenograft model, providing a promising HER2 nanoCAR for further (pre)clinical investigation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Vrije Universiteit Brussel (VUB), Translational Oncology Research Center, Department of Biomedical Sciences, Molecular and Cellular Therapy Research Group, Brussels, Belgium.
- Vrije Universiteit Brussel (VUB), Department of Medical Imaging (MIMA), Molecular Imaging and Therapy (MITH) Research Group, Brussels, Belgium.
- Vrije Universiteit Brussel (VUB), Translational Oncology Research Center, Department of Biomedical Sciences, Hematology and Immunology Research Group, Brussels, Belgium.
- EsoBiotec, Mont Saint Guibert, Belgium.
Förderung
- Fonds Wetenschappelijk Onderzoek
- Vrije Universiteit Brussel
- Kom op tegen kanker
Zitieren
APA
Meeus, F., Van der Vreken, A., Autaers, D., De Groof, T. W. M., Esprit, A., Franceschini, L., Parone, P., Goyvaerts, C., De Vlaeminck, Y., Devoogdt, N., & Breckpot, K. (2025). Preclinical development and selection of nanobody-based CAR-T cells targeting HER2-positive solid tumors. Molecular Therapy Oncology, 33(4), 201088. https://doi.org/10.1016/j.omton.2025.201088
Vancouver
Meeus F, Van der Vreken A, Autaers D, De Groof TWM, Esprit A, Franceschini L, et al. Preclinical development and selection of nanobody-based CAR-T cells targeting HER2-positive solid tumors. Molecular Therapy Oncology. 2025;33(4):201088. doi:10.1016/j.omton.2025.201088
BibTeX
@article{Meeus2025,
author = {Meeus, Fien and Van der Vreken, Arne and Autaers, Dorien and De Groof, Timo W M and Esprit, Arthur and Franceschini, Lorenzo and Parone, Philippe and Goyvaerts, Cleo and De Vlaeminck, Yannick and Devoogdt, Nick and Breckpot, Karine},
title = {Preclinical development and selection of nanobody-based CAR-T cells targeting HER2-positive solid tumors},
journal = {Molecular Therapy Oncology},
year = {2025},
volume = {33},
number = {4},
pages = {201088},
doi = {10.1016/j.omton.2025.201088}
}
EUVIMED